美國 豪洛捷 Hologic www.hologic.com
Hologic公司于1986年由前任總裁和董事長S. David Ellenboger和首席技術(shù)總監(jiān)Jay A. Stein創(chuàng)辦，是一家致力于滿足女性健康醫(yī)療，提供最先進的醫(yī)學(xué)影像系統(tǒng)的公司。
Hologic公司自創(chuàng)辦起，就一直致力于開發(fā)和提供日益發(fā)展的醫(yī)學(xué)影像系統(tǒng)，以滿足現(xiàn)代醫(yī)學(xué)女性健康醫(yī)療的需要。它首先開發(fā)出最先進的放射學(xué)數(shù)字影像技術(shù)并應(yīng)用于乳腺照像。當前Hologic公司的業(yè)務(wù)主要集中在骨質(zhì)疏松檢測系統(tǒng)、乳腺照像和乳腺活組織檢測系統(tǒng)、數(shù)字化X線檢測系統(tǒng)以及適用于骨科小型C型臂檢測系統(tǒng)。
1987年，Hologic公司在骨密度檢測方法中取得突破，是首家推出雙能X線骨密度儀（DXA）的公司。目前Hologic公司還在不斷開發(fā)、生產(chǎn)和銷售X線骨密度儀和超聲骨分析儀，以用于臨床骨質(zhì)疏松的預(yù)防和治療。公司生產(chǎn)的是數(shù)字化放射檢測系統(tǒng)（QDR）已在X線骨密度儀中得到應(yīng)用，通過精確測量骨密度，大大提高了骨質(zhì)疏松癥的診斷水平，并能對包括骨質(zhì)疏松在內(nèi)的骨代謝疾病的治療進行良好的監(jiān)測。
Hologic公司正在繼續(xù)努力以保證其在該領(lǐng)域的領(lǐng)先水平，最引人注目的是最近新研發(fā)生產(chǎn)的Discovery QDR系列骨密度儀和脊椎快速評價技術(shù)的應(yīng)用。
Hologic公司生產(chǎn)的骨密度儀目前已遍布許多先進的醫(yī)學(xué)院校、研究機構(gòu)和骨質(zhì)疏松領(lǐng)域里一些著名專家的實驗室。在全球已有10000臺在工作.

豪洛捷（中國）企業(yè)管理咨詢有限公司
辦公地址：海淀區(qū)西直門北大街32號楓藍國際中心A座1005
郵編：100082
電話：010-62290000
傳真：010-62290100
E-mail:info@tctmedical.com

北京好樂杰醫(yī)療器械有限公司
地址：北京大興工業(yè)開發(fā)區(qū)金輔路8號 
郵政編碼：102600 
通信地址：北京市朝陽區(qū)合生麒麟社3號樓207郵編：100102
全國熱線：400-6506-032
電話：(010)57389015 
(010)57389075
傳真：(010)57389015 
Email:healthcoming@china.com

美中互利(北京)國際貿(mào)易有限公司 
地址：北京市朝陽區(qū)朝陽北路237號復(fù)星國際中心28層 郵編:100020 　
電話：010-65528822 　 　 　 　 　 　 　
傳真：010-65528833 010-65528375

HOLOGIC亞太總部: 
地址： 香港新界沙田科學(xué)園西路11號，香港科學(xué)園2號生物技術(shù)中心7層 
電話： (852) 3748 7700 
公司網(wǎng)址： http://www.hologic.com 
郵箱： asia@hologic.com 

Hologic, Inc. (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems, and surgical products dedicated to serving the healthcare needs of women throughout the world.
Historically, Hologic developed, manufactured, and marketed products focused on mammography, breast care, and osteoporosis assessment. In 2007, we expanded our focus and now provide a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arms for extremity imaging, and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. We are proud of this achievement, and conscious of the responsibility that our leadership position brings with it. We believe that the health issues facing women today deserve and demand the singular dedication of a passionate company.
Our core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health.
Breast Health
"You have cancer. Fortunately, we caught it early."
Hologic's largest business is breast cancer diagnosis and treatment. Each year, more than one million women in the U.S. are diagnosed with breast cancer, while hundreds of thousands of them fall victim to this dreaded disease. One out of eight American women will get breast cancer in her lifetime. Fortunately when breast cancer is detected and treated in its earliest stages, the five-year survival rate is 98 percent.
In 2007, 92 percent of the mammography breast cancer screening systems sold in the United States were digital. The Hologic Selenia™ system is at the forefront of this wave, setting a standard for excellence in digital mammography.
We continue to introduce advances in imaging and interpretation, such as the first tungsten x-ray tube with a special silver filter that allows digital mammography images to be acquired at a lower radiation dose and shorter exposure times. We have integrated the R2™ computer-aided detection (CAD) into our SecurView™ diagnostic workstations, giving clinicians a sophisticated pattern recognition software tool to help find cancers at an early stage.
Hologic is helping imaging centers deliver a "high-tech, soft-touch" experience with the MammoPad® radiolucent breast cushion. The MammoPad cushion provides patient comfort, while aiding in breast positioning, compression, and tissue acquisition.
Each year in the U.S. there are more than 600,000 open surgical breast biopsies. An estimated 80 percent of results are negative. The cost, risk, and trauma of these surgeries are enormous. Less invasive alternatives can drive down healthcare costs, support clinical efficiency, and, most importantly, cause far less distress for patients. Just as we are at the forefront of driving better detection solutions, our goal is to lead the industry in developing innovative technologies that make less invasive and more effective intervention possible and preferred.
Our MultiCare® Platinum stereotactic prone biopsy table and StereoLoc® II and digital StereoLoc II breast biopsy systems are designed to facilitate highly precise, image-guided procedures under minimally invasive conditions. We offer a wide number of interventional breast biopsy solutions including ATEC® percutaneous, automatic vacuum assisted breast biopsy systems, Celero® and Eviva™ ancillary biopsy devices, and a full line of biopsy site markers designed to provide compassionate care for every woman facing a breast cancer diagnosis.
When a cancer diagnosis is confirmed and radiation treatment is required, our MammoSite® targeted radiation therapy gives women a less traumatic alternative to mastectomies and whole breast irradiation. Using MammoSite therapy, clinicians can deliver a site-specific radiation dose inside the breast, reducing exposure to surrounding healthy tissue and organs. Four-year analysis of the MammoSite radiation therapy system has found that breast cancer recurrence rates with the MammoSite system continue to be comparable to the rates reported with standard radiation therapy.